Merck to stop testing Isentress after initial trial results
Merck said that they settled to stop testing Isentress, the company's HIV drug, after initial trial results showed that the treatment was not as useful as control treatment.
Merck & Co. said it achieved positive results in Phase 3 trials of its experimental insomnia treatment, a key drug in the pharmaceutical giant's pipeline.